Topotarget

March 2010

BUYER

Spepharma Holding BV, a Dutch pharmaceutical company acquired the EU product rights and Spectrum Pharmaceuticals, Topotarget´s US partner, acquired the US product rights.

TARGET

SAVENE is an approved treatment in the EU and US for anthracycline extravasation i.e. unintentional leakage of cytotoxic chemotherapy from the vein into surrounding tissue during administration. The product was launched in 2006 and has total sales of EUR 3 million.

SELLER

Topotarget A/S, a Danish listed orphan oncology company focused on late-stage clinical development. Topotarget aims at improving the quality of life and prolonging the lives of cancer patients by offering novel, safe, and effective cancer drugs.

TRANSACTION

An negotiated transaction including a selected number of industrial buyers.